Vatorsecurities.se använder sig av cookies för att ge dig som besökare en så bra upplevelse som möjligt.

News

Unlocking US reimbursement – the share price catalyst during 2021

16 April 2021

SciBase is delivering as we expected, and the share price is closing in on our target price. Recent news flow confirms the Nevisense EIS-technology’s potential for skin barrier assessment applications – an upside to both our and the market’s valuation of the company.

The apparent tangible driver of the share price for the coming 12 months, however, is unlocking US reimbursement (Medicare) where the US company DermTech offers a clear blueprint.

Read More

Vator Securities advises Respiratorius on 25 MSEK Directed Share Issue

13 April 2021

Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 25 million.

Respiratorius AB is developing drug candidates with the goal to launch drugs for common diseases cancer, chronic obstructive pulmonary disease (COPD) and severe asthma. In addition, the project portfolio is a project for improved diagnosis of certain cardiovascular diseases.

Read More

Vator Securities advises Sprint Bioscience on 21 MSEK Directed Share Issue

8 April 2021

Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 21 million.

Sprint Bioscience develops small-molecule first-in-class drug projects with a focus on oncology. With a fragment-based drug development method, the company develops drug projects in a time- and resource-efficient way that is outlicensed to global pharmaceutical companies during the preclinical phase.

Read More

Vator Securities advises Epulze on 57 MSEK Private Placement

6 April 2021

Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 57 million.

Epulze gives amateur players of computer games like Dota 2 and Counter-Strike: Global Offensive, the opportunity to participate in tournaments, leagues, and matches where real money is at stake. Among the new investors are well-known names such as Svea Ekonomi and Norwegian Carucel Finance, while Knutsson Holdings increases its ownership in the company.

Read More

Thou shall reimburse the one who finds the silent killer

29 March 2021

It may seem trivial to point out by now, but an accurate distinction between surveillance and screening is important in order to properly understand IMMray PanCan-d’s intended use, clinical utility offer and the parameters of importance to access the viability of the test to be included in guidelines and gaining broad reimbursement.

We still see confusion here.

Read More

Vator Securities advises CombiGene on 75 MSEK Rights Issue

8 March 2021

Vator Securities acts as Financial Adviser in connection with the transaction raising approximately SEK 75 million.

Having established the production platform for CG01, CombiGene’s intention in 2021 is to focus on the final parts of the preclinical program for CG01 with two major preclinical studies, a biodistribution study and a safety study, which will be conducted together with CombiGene’s CRO partners Northern Biomedical Research and Neurochase.

Read More

Vator Securities Tech Days

15 February 2021

Vator Securities Tech Days are investor events with some of the most interesting and fast-growing tech companies in the Nordics.

Vator Securities presents a focused insight into the spectrum of tech companies including expert sessions related to the tech industry.

Read More

IBD Junior Analyst – Corporate Finance till Vator Securities

15 January 2021

Som junior analytiker kommer fokus ligga på att assistera dina kollegor vid framtagandet av företagspresentationer, arbeta med research, samt bistå med administration kring transaktioner och projekt.

Teamet består idag av 9 personer och kommer att utökas med ytterligare juniora talanger.

Read More